No Data
No Data
Zhī Tōng Hong Kong Stocks Repurchase Statistics | October 11th
Hong Kong Stock Buyback Statistics | October 11th
Pharmaron - B (02142) repurchased 8,000 shares on October 10th.
Pharmaceutical Company B (02142) announced that it will spend 0.0108 million Hong Kong dollars to repurchase... on October 10, 2024.
The results of the Phase I clinical study of the innovative therapy Prusubaedonecept combined with anti-PD-1 antibody for the treatment of advanced melanoma and other solid tumors by Boao Pharmaceutical have been published.
On October 10, 2024, in Suzhou, China, Cambridge, Massachusetts, USA, and Rotterdam, the Netherlands / PRNewswire / - Hapo BioMed (stock code: 02142.HK), a global biomedical company focused on innovative antibody therapy discovery, development, and commercialization in the fields of oncology and immunology, announced today that the world's first fully humanized heavy chain antibody targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) PruSuzabamab (HBM4003) in combination with anti-PD-1 antibody Trepilumab for the treatment of advanced solid tumors (especially melanoma) Phase I clinical trial results have already been.
A Piece Of The Puzzle Missing From HBM Holdings Limited's (HKG:2142) 34% Share Price Climb
Express News | Hbm Holdings Acquires Calcium Products
HBM Holdings Acquires Calcium Products
No Data
No Data